This workshop will focus on how inducible pluripotent stem cells (iPSCs) can be used to produce liver cells and organoids. These are exciting new tools for experimental hepatology and hold great promise for clinical hepatology. The generation of iPSC-derived liver cells enables studies of the pathophysiology of several human conditions and to explore the effects of new drugs and treatment following a personalized medicine approach.
The main objective of this program is to educate medical students or residents who are considering a career in hepatology about training opportunities as well as arm the current GI and/or hepatology fellows with knowledge to help them succeed in academic hepatology. Time will be decidated specifically to discussion of clinical and basic science research, funding mechanisms, mentorship and important career crossroads. An overview of the responsibilities and opportunities of an academic hepatologist and clinician educator will all be provided.
As the practice of hepatology has matured over the past decade many AASLD members have successfully developed or transitioned to community-based hepatology practices in one of three major areas: a community based health care system, a multi-speciality group practice or a hepatology-only medical practice.
This program will address the various designs used in patient-oriented research, including the strengths and limitations to each approach as well as the impact each technique has had on the study and care of patients with liver disease. In addition, approaches to obtaining funding for such research, as well as the development and use of quality measures for the care of patients with chronic liver disease will be discussed.
This program is intended to explore current and novel health care delivery approaches and strategies for managing populations affected by cirrhosis and portal hypertension. In contrast to disease-based symposium focused on novel diagnostic and treatment approaches, this program intends to focus on current and evolving approaches inspired by delivery system reform to ensure that high quality, patient-centered, and resource efficien medical care is delivered to large segments of patients with advanced liver disease. The emphasis of this program is on clinical knowledge.Michael Volk Brett E.
Colleen N. Feriod, Andre Gustavo Oliveira, Mateus T. Guerra, Lily Nguyen, Kisha Mitchell Richards, Michael J. Jurczak, Hai‐Bin Ruan, Joao Paulo Camporez, Xiaoyong Yang, Gerald I. Shulman, Anton M. Bennett, Michael H. Nathanson, Barbara E. Ehrlich – 11 November 2016 – Fatty liver is the most common type of liver disease, affecting nearly one third of the U.S. population and more than half a billion people worldwide. Abnormalities in endoplasmic reticulum (ER) calcium handling and mitochondrial function each have been implicated in abnormal lipid droplet formation.
Nicolas Goossens, Yujin Hoshida – 10 November 2016
Nicolas M. Intagliata, Carlos N. Ferreira, Stephen H. Caldwell – 10 November 2016
Steven L. Flamm – 10 November 2016
Sophoclis P. Alexopoulos, Victor Nekrasov, Shu Cao, Susan Groshen, Navpreet Kaur, Yuri S. Genyk, Lea Matsuoka – 10 November 2016 – The majority of pediatric patients with end‐stage liver disease receive a transplant with a whole liver (WL) allograft. However, smaller recipients with biliary atresia (BA) may have improved outcomes with deceased donor partial liver (DDPL) or living donor allografts. This study compares the national outcomes for liver transplantation in BA, with attention to the interaction between liver allograft type and recipient size.